Clinical Trial

Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2025 (before its estimated November 25, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, open-label, single-center, Phase II clinical trial. Thirty patients with HER2-negative gastric adenocarcinoma or gastroesophageal junction (GEJ) cancer, presenting with PAN metastasis (No. 16 lymph nodes ≥10 mm), will be enrolled. Participants will receive four cycles of conversion immunochemotherapy with a PD-1 inhibitor (Serplulimab) combined with the SOX chemotherapy regimen (oxaliplatin and S-1). After completion of conversion therapy, patients will undergo curative minimally invasive (laparoscopic or robotic) gastrectomy with D2+PAND lymphadenectomy
Trial Details
NCT Number NCT07056010
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Gastric Cancer
Enrollment 30 participants
Start Date 2024-11-25
Primary Completion 2025-11-25 (estimated)
Study Completion 2028-11-25 (estimated)
Updated on ClinicalTrials.gov 2025-07-09